Home/Filings/4/0001104659-05-035138
4//SEC Filing

TRANSKARYOTIC THERAPIES INC 4

Accession 0001104659-05-035138

CIK 0000885259operating

Filed

Jul 28, 8:00 PM ET

Accepted

Jul 29, 4:43 PM ET

Size

13.5 KB

Accession

0001104659-05-035138

Insider Transaction Report

Form 4
Period: 2005-07-27
FUCHS RENATO
Sr. VP- Manufacturing & Op.
Transactions
  • Disposition to Issuer

    Stock Option (right to buy)

    2005-07-27$13.21/sh25,000$330,2500 total
    Exercise: $23.79Exp: 2015-03-24Common Stock (25,000 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2005-07-27$31.16/sh20,000$623,2000 total
    Exercise: $5.84Exp: 2013-03-28Common Stock (20,000 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2005-07-27$27.24/sh15,000$408,6000 total
    Exercise: $9.76Exp: 2013-06-11Common Stock (15,000 underlying)
Footnotes (4)
  • [F1]This option, which was granted on March 24, 2005 and provided for vesting in three approximately equal annual installments beginning on March 24, 2006, was cancelled pursuant to a merger agreement among the Issuer, Shire Pharmaceuticals Group plc and Sparta Acquisition Corporation, dated April 21, 2005, in exchange for a cash payment of $330,250, representing the excess of $37.00 over the per share exercise price of the option multiplied by the number of shares subject to the option, whether vested or unvested.
  • [F2]This option, which was granted on March 24, 2004 and provided for vesting in three approximately equal annual installments beginning on March 24, 2005, was cancelled in the merger in exchange for a cash payment of $659,500, representing the excess of $37.00 over the per share exercise price of the option multiplied by the number of shares subject to the option, whether vested or unvested.
  • [F3]This option, which was granted on June 11, 2003 and provided for vesting in four equal semi-annual installments beginning on December 11, 2003, was cancelled in the merger in exchange for a cash payment of $408,600, representing the excess of $37.00 over the per share exercise price of the option multiplied by the number of shares subject to the option, whether vested or unvested.
  • [F4]This option, which was granted on March 28, 2003 and provided for vesting in four equal semi-annual installments beginning on September 28, 2003, was cancelled in the merger in exchange for a cash payment of $623,200, representing the excess of $37.00 over the per share exercise price of the option multiplied by the number of shares subject to the option, whether vested or unvested.

Documents

1 file

Issuer

TRANSKARYOTIC THERAPIES INC

CIK 0000885259

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0000885259

Filing Metadata

Form type
4
Filed
Jul 28, 8:00 PM ET
Accepted
Jul 29, 4:43 PM ET
Size
13.5 KB